Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 105

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 8
Chunk 105
---
 to execute on our strategic plan;

•increased costs of reagents and other consumables required for testing;

•increased personnel and facility costs;

•our inability to hire competent, trained staff, including laboratory directors required to review and approve all reports we issue in our business, and sales personnel;

•our inability to obtain necessary equipment or reagents to perform testing;

•our inability to increase production capacity to meet demand increases;

•our inability to expand into new markets;

•increased licensing or royalty costs, and our ability to maintain and enforce the intellectual property rights underlying our tests and services;

31

•changes in intellectual propriety law applicable to our patents or enforcement in the United States and foreign countries;

•the expiration of the patents covering our products;

•potential obsolescence of our tests;

•our inability to obtain or increase commercial acceptance of our tests;

•increased competition and loss of market share;

•global or local economic conditions;

•protectionist laws and business practices, including trade restrictions, tariffs, export controls, quotas and other trade barriers, including China-U.S., Mexico-U.S. and Canada-U.S trade policies;

•increased regulatory requirements; 

•material litigation costs, settlements, and judgments;

•our increased investment in research and development, including the possibility that new products may fail to achieve clinical validation, regulatory clearance, or market acceptance; and

•our inability to successfully execute our plan to leverage strategic collaborations and biopharma partnerships, which arrangements may not be available on acceptable terms, or at all,  delayed, modified, or terminated, any of which could  potentially affect our ability to launch or commercialize new testing solutions.

The failure to achieve our growth targets and achieve and/or maintain revenue growth and profitability for our business could have a material adverse effect on our business, prospects, financial condition, results of operations, cash flows, as well as the trading price of our common stock.

An inability to attract and retain experienced and qualified personnel, including key management personnel, could  adversely affect our business. 

Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain highly qualified and experienced personnel, including key management personnel. Competition for these personnel is intense, especially for management, sales, scientific, medical, information technology, research and development and other technical personnel. We may not be able to attract or retain qualified personnel in the future due to the competition for qualified personnel among life science and technology businesses as well as universities and public and private research institutions.